Immune Mediated Mechanisms of Resistance to Daratumumab
| العنوان: | Immune Mediated Mechanisms of Resistance to Daratumumab |
|---|---|
| المؤلفون: | Estelle Troadec, James F. Sanchez, Domenico Viola, Xiwei Wu, Flavia Pichiorri, Michael Rosenzweig, Amrita Krishnan, Ada Dona, Ashish Streatfield, Jonathan J Keats, Lucy Ghoda, Myo Htut, Chatchada Karanes, Emine Gulsen Gunes, Guido Marcucci, Tinisha McDonald, Sergio Branciamore, Steven T. Rosen |
| المصدر: | Blood. 132:3201-3201 |
| بيانات النشر: | American Society of Hematology, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.drug_class, Immunology, Cell Biology, Hematology, Biology, CD38, Dara, Monoclonal antibody, Biochemistry, Molecular biology, Epitope, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Immune system, medicine.anatomical_structure, immune system diseases, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, medicine, biology.protein, Bone marrow, Antibody, Clone (B-cell biology) |
| الوصف: | Introduction: Daratumumab (Dara) is a human monoclonal antibody targeting the highly expressed multiple myeloma (MM) surface receptor CD38, with significant activity in relapsed MM. However, resistance to Dara develops in virtually all patients (pts). Thus, in order to maximize its clinical activity and prevent resistance, it is imperative to understand why pts stop responding. Our group recently reported that, in addition to the malignant cells, several immune-effector cells also express CD38. Thus, we hypothesized that the expression of CD38 or lack of it on non-cancer immune cell-subsets may also play a role in both clinical response and resistance to Dara. Results: To address our hypothesis, we analyzed CD38 surface expression in CD138+ MM cells isolated from 5 Dara-naïve (D-naïve) pts and from 8 Dara progressing pts (D-prg) who had discontinued Dara therapy for at least 4 weeks prior to analysis. We observed that the CD138+ MM-cells of D-prg displayed a lower median fluorescence intensity (MFI) of CD38 compared to the MFI of MM cells isolated from the D-naïve (p=0.04); no significant difference was however observed in the percentage of CD38+ MM cells between the two groups. In fact, all of the MM cells expressed CD38 in both D-naïve and D-prg, supporting the hypothesis that resistance to Dara was not mediated by loss of CD38 expression on MM cells. Next, we looked at whether CD38 on the surface of MM cells from D-prg was still recognizable by Dara. Thus, we treated MM cells ex-vivo with Dara at the clinically achievable concentration of 100 μg/ml. We showed that Dara was still able to bind CD38 on the surface of the D-prg CD138+ MM cells, since, after Dara treatment, no CD38+ signal was detected upon staining with a CD38 monoclonal antibody sharing the same targeting CD38 epitope (clone IB6) (Fig.1a). Conversely, we detected a CD38+ signal when a different anti-human CD38 multi-epitope antibody was used in a similar experiment (Cytognos) (Fig.1b). CD38 mRNA expression was observed in all MM cells isolated from D-prg, and we were not able to identify any missense mutations in CD38 mRNA from MM cells of D-prg for whom material was available for analysis. Thus, having demonstrated that resistance to Dara was not related to the expression of CD38 on the MM-cells, we turned our attention to the MM bone marrow (BM) microenvironment (ME). We performed RNA-sequencing of the BM-ME depleted of the CD138+ MM cells obtained from the D-prg (n=5) and D-naïve (n=5). A gene expression signature differentiated the two groups. In D-prg, we observed a significant downregulation (fold-change Conclusions: Our data are supportive of the hypothesis that loss of Dara binding to MM-cell surface CD38 or the complete loss of CD38 on MM cells may not necessarily be the cause of Dara treatment resistance. We instead propose that Dara binding on CD38+ immune effector cells may be critical and that the loss of CD38 expression on these cells can lead to mechanisms of Dara-acquired resistance. Disclosures Rosenzweig: Celgene: Speakers Bureau. Krishnan:Celgene: Consultancy, Equity Ownership, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Sutro: Speakers Bureau; Takeda: Speakers Bureau; Onyx: Speakers Bureau. |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::4e8bb7f2526dcfaa56be1931cf9b4cdfTest https://doi.org/10.1182/blood-2018-99-117441Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........4e8bb7f2526dcfaa56be1931cf9b4cdf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|